Our new EVP of R&D, Zachary J Roberts MD PhD shares why he joined Allogene and why he is passionate about using his experience in cell therapy to lead the next revolution in CAR T.
Allogene Therapeutics’ Post
More Relevant Posts
-
We’re pioneering a new approach to LBCL treatment with our groundbreaking ALPHA3 trial that aims to identify and treat patients as part of the 1L regimen, potentially transforming the standard of care. $ALLO #CART #celltherapy #immunotherapy
-
David Chang, MD, PhD, President, and CEO of Allogene will join a panel next Monday at the virtual Canaccord Horizons in Oncology Conference. Watch the webcast in the investors section of our website. $ALLO #CART #celltherapy #immunotherapy
-
-
Congratulations to Owen Witte, MD, on receiving the American Association for Cancer Research Award for Outstanding Achievement in Blood Cancer Research.
-
-
At Allogene, we’ve rewritten the CAR T playbook. Our approach to development and trial design has the potential to deliver ‘off-the-shelf’ CAR T products that do what autologous CAR T therapies cannot. $ALLO #CART #celltherapy #immunotherapy
-
-
Allogeneic CAR T has the potential to redefine the future of CAR T. Learn how we are leveraging the unique attributes of investigational AlloCAR T™ products to meet the current and future needs of patients and dramatically expand access to treatment. $ALLO #CART #celltherapy #immunotherapy Discover the Allogeneic Advantage: www.allogene.com
-
-
Pleased to report our Q4 and Full Year 2023 corporate update and business highlights. https://lnkd.in/gNaEm66R
-
We are pleased to announce our collaboration with Arbor Biotechnologies for use of their CRISPR gene-editing technology to develop allogeneic CAR T products for autoimmune disease. #CART $ALLO #celltherapy #immunotherapy
-
-
Read more about how investigational allogeneic CAR T products are going where autologous therapies can not. $ALLO #CART #celltherapy #immunotherapy https://lnkd.in/gTn4AHNK
‘Off-the-shelf’ CAR T may hold the key to dramatically expanding patient access
https://www.statnews.com
-
Join us for our Q4 and full year 2023 conference call on Thursday, March 14 at 2:00 p.m. PT / 5:00 p.m. ET. A webcast will be available on the investor section of our website. $ALLO https://lnkd.in/gxUmX34m
